WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Filters
List of articles in category Bayer
Title Published Date
FDA Grants Fast Track Designation to Bayer's Investigational Compound Alpharadin™ 23 August 2011
Bayer to support WHO and Stop Tuberculosis Partnership in fighting tuberculosis 15 August 2011
Results of ROCKET AF Study of Bayer’s Xarelto® (Rivaroxaban) 11 August 2011
Bayer continues positive momentum 01 August 2011
Bayer advances research in the area of pulmonary hypertension 01 July 2011
Major Subgroup Analysis Shows Bayer's Rivaroxaban is Highly Effective in the Prevention of Recurrent Strokes 26 May 2011
Bayer off to a successful start to 2011 02 May 2011
Bayer affirms the positive benefit-risk profile of its drospirenone- containing oral contraceptives 26 April 2011
Bayer's Rivaroxaban Submitted for Approval in Japan 15 April 2011
Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 11 April 2011
OncoTrack: A new International consortium launches project in the area of genomic cancer diagnostics 13 March 2011
Bayer extends support to fight Chagas disease 04 March 2011
Breaking the Taboo Associated with Hemorrhoidal Disease 02 March 2011
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy 24 February 2011
FDA Grants Orphan Drug Designation to Regorafenib for the Treatment of Gastrointestinal Stromal Tumors 09 February 2011
Bayer and Zydus Cadila sign Joint Venture Agreement 30 January 2011
Bayer and Regeneron start MYRROR Phase III Trial 19 January 2011
New Bayer U.S. Innovation Center starts its operations 12 January 2011
Bayer: 35 million Euros for the expansion of the development of biologicals 13 December 2010
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye 23 November 2010
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare
  • Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
  • An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission
  • European Commission authorizes COVID-19 vaccine Moderna in Europe

Research & Development

  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system
  • New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
  • Sustained cellular immune dysregulation in individuals recovering from COVID-19
  • How SARS-CoV-2 interacts with cells
  • Neutralizing antibodies protect against severe COVID-19

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Bayer
  4. Bayer raises its brand profile

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.